Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sanford J. Madigan
AddedMar 31, 2024
UpdatedMay 31, 2026
Sanford J. Madigan

Sanford J. Madigan

Founder, Cellular Approaches

CrunchbaseLinkedIn

Sanford J. Madigan's Career

Cellular Approaches
Cellular Approaches

Los Angeles, CA, US

Founder
Nerio Therapeutics
Nerio Therapeutics

Los Angeles, CA, US

CEO· C-Suite · Management
Ankasa Regenerative Therapeutics
Ankasa Regenerative Therapeutics

Los Angeles, CA, US

Co-Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sanford J. Madigan's Career

Cellular Approaches
Cellular Approaches
Seed$2.6M52016Los Angeles, CA, US
Founder

Similar to Cellular Approaches

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
HebeCellHebeCellNatick, MA, USCell Therapiesest. 2016HebeCellNatick, MA, US · est. 2016

MA-based HebeCell pioneers in immuno-oncology and regenerative medicine through cell-based therapeutics.

Series A · $63M24
Cellevolve BioCellevolve BioSan Francisco, CA, USCell Therapyest. 2020Cellevolve BioSan Francisco, CA, US · est. 2020

San Francisco-based cell therapy provider, partnering with global innovators to advance and commercialize novel therapeutics.

Seed · $6M9
Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Nerio Therapeutics
Nerio Therapeutics
Series A$6.5M62019Los Angeles, CA, US
CEO· C-Suite · Management

Leadership at Nerio Therapeutics

Jay LichterJay LichterCo-Founder
Tighe ReardonTighe ReardonCo-Founder

Similar to Nerio Therapeutics

Nerx BiosciencesNerx BiosciencesIndianapolis, IN, USCancer TherapeuticsNerx BiosciencesIndianapolis, IN, US

US-based NĒRx BioSciences Inc, founded in 2009, specializes in discovering and developing targeted cancer therapeutics.

Seed · $500k11
Nerium BiotechnologyNerium BiotechnologySan Antonio, TX, USPharmaceuticalsest. 2006Nerium BiotechnologySan Antonio, TX, US · est. 2006

Nerium Biotech, a US-based company, develops oleander-based products for treating cancer, HIV/AIDS, Hepatitis C, and aging skin.

Public · $288.5k33
Enlaza TherapeuticsEnlaza TherapeuticsLos Angeles, CA, USBiotechnologyest. 2020Enlaza TherapeuticsLos Angeles, CA, US · est. 2020

Enlaza Therapeutics: A California-based biotech research firm, founded in 2020.

Seed · $61M33
Nereid TherapeuticsNereid TherapeuticsBoston, MA, USDrug Discoveryest. 2020Nereid TherapeuticsBoston, MA, US · est. 2020

Nereid Therapeutics: Innovating drug discovery with proprietary technologies for new disease treatments.

Series A · $50M12
Ankasa Regenerative Therapeutics
Ankasa Regenerative Therapeutics
Series A$14.5M3k2014Los Angeles, CA, US
Co-Founder & CEO· C-Suite · Management

Leadership at Ankasa Regenerative Therapeutics

Jill HelmsJill HelmsCo-Founder

Similar to Ankasa Regenerative Therapeutics

APstem TherapeuticsAPstem TherapeuticsFremont, CA, USStem Cell Therapiesest. 2017APstem TherapeuticsFremont, CA, US · est. 2017

APstem Therapeutics: Advancing stem cell discoveries to combat diseases and aging challenges.

Seed · $4.3M6
StemgenicsStemgenicsSeattle, WA, USStem Cells, Therapeuticsest. 2008StemgenicsSeattle, WA, US · est. 2008

Stemgenics develops technology to convert mature skin cells into personalized stem cells for tissue regeneration.

Angel · $3.5M3
Aspen NeuroscienceAspen NeuroscienceSan Diego, CA, USStem Cell Therapiesest. 2018Aspen NeuroscienceSan Diego, CA, US · est. 2018

Aspen develops patient-specific therapies using innovative stem cell technology.

Series D · $264M112
Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175

Sanford J. Madigan's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Sanford J. Madigan

Ken LeonardKen LeonardCo-Founder · JoyflipsSonja McKinlaySonja McKinlayFounder · NeriTony GiordanoTony GiordanoFounder · TheraVascTom WilderTom WilderBoard Member · Vensana CapitalSandra PanemSandra PanemBoard Member · Acorda Therapeutics